media – Page 6 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Smegglutide clinical trial failed

On November 24, Novo Nordisk announced that semaglutide failed in two Phase III clinical trials (EVOKE and EVOKE+) for Alzheimer’s disease, failing to meet the primary efficacy endpoint. EVOKE and EVOKE+ are international, multicenter, randomized, double-blind, placebo-controlled phase III clinical trials that enrolled a total of 3,808 patients aged 55-85 with early symptomatic Alzheimer’s disease (1,855 for EVOKE and 1,953 for EVOKE+), including those in the mild cognitive impairment (MCI) and mild dementia stages. The trial used an oral semaglutide 14 mg once daily dosing regimen, with the target dose achieved through 8-week dose escalation (3 mg → 7 mg → 14 mg), for a total treatment duration of 156 weeks (104 weeks of primary treatment + 52 weeks of extension treatment). The primary endpoint of the trial was the change in the Clinical Dementia Rating Scale-Sum (CDR-SB) score relative to baseline at week 104. The CDR-SB scale assesses six ...
- Source: drugdu
- 51
- November 27, 2025
Walvax Biotech’s 13-valent Pneumococcal Conjugate Vaccine Granted Market Approval in Egypt

Beijing Business Today, Nov. 26 — Walvax Biotech announced that its subsidiary, Yuxi Walvax Biotech Co., Ltd., has received the “Biological Product Marketing Authorization” issued by the Egyptian Drug Authority (EDA) for its 13-valent Pneumococcal Polysaccharide Conjugate Vaccine, signifying that the vaccine has obtained marketing approval in Egypt. According to the announcement, the 13-valent Pneumococcal Conjugate Vaccine developed by Yuxi Walvax is primarily indicated for infants and children from 6 weeks up to 5 years of age (before their 6th birthday). It is designed to prevent infectious diseases caused by the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) included in the vaccine. This vaccine was initially approved for marketing in China back in 2020. Reference: https://finance.eastmoney.com/a/202511263575601059.html
- Source: drugdu
- 53
- November 27, 2025
Why Is Flu Vaccination So Hard to Promote?

During each flu season, the rapid surge in influenza cases within a short period can place tremendous pressure on healthcare facilities. Receiving the flu vaccination is regarded as the “first line of defense” against influenza, significantly reducing the risk of infection and severe complications among recipients. However, the influenza vaccination rate in China has long remained at an unsatisfactory level, lingering in the single digits. Compared to the market for influenza treatment drugs, sales in the flu vaccine market have consistently underperformed. Flu vaccine sales are outsold by influenza treatment drugs A Yicai reporter compiled the 2024 sales data of influenza vaccine companies listed on the A-share and Hong Kong stock markets. The main A-share influenza vaccine enterprises include Hualan Vaccine (301207.SZ), GDK Bio (688670.SH), and BCHT (688276.SH). The primary Hong Kong-listed influenza vaccine company is Zhonghui Biotech (02627.HK). From 2021 to 2024, Hualan Vaccine consistently maintained the leading position ...
- Source: drugdu
- 81
- November 27, 2025
Additional clinical trial data for pediatric patients is needed. Tian Tan Biologics has withdrawn its application for the market release of a hemophilia treatment drug.

More than 10 months after its submission, Tian Tan Biologics (SH600161, stock price 17.61 yuan, market capitalization 34.822 billion yuan) withdrew its application for listing of a hemophilia drug that cost 266 million yuan to develop. On the evening of November 19th, this leading domestic blood product company released a statement, stating that its subordinate enterprise, Chengdu Rongsheng Pharmaceutical Co., Ltd. (hereinafter referred to as Chengdu Rongsheng), withdrew the drug registration application for “Recombinant Human Coagulation Factor VIIa for Injection”. The reason was that according to the review opinions of the CDE (National Medical Products Administration Drug Evaluation Center), supplementary information was required. It became the first domestically produced recombinant human coagulation factor VIIa biological product to be approved for market launch in China. However, from the indication perspective, Anqixin’s application scope is much smaller than Nuoqi. The products under Tian Tan Biotechnology are more similar to Nokir. On December ...
- Source: drugdu
- 54
- November 27, 2025
CSPC Pharmaceutical Group Limited ‘s clinical trial for the recombinant fully human anti-ACTRIIA/IIB monoclonal antibody has been approved

Beijing Business News (Reporter Wang Yinhao, Song Yuying) – On November 26th, Shigao Group announced that the recombinant fully human anti-ActRIIA/IIB monoclonal antibody drug (JMT206) developed by the group has been approved by the National Medical Products Administration and can conduct clinical trials in China. The announcement shows that this product can specifically bind to both activin receptor type IIA and type IIB simultaneously, blocking the binding of activin A, myostatin, and growth differentiation factor 11 to activin receptor type II, thereby inhibiting the activation of downstream signaling pathways, reducing muscle loss, and promoting the maintenance and growth of skeletal muscles, achieving the effect of muscle gain and fat loss. At the same time, this product can also assist GLP-1 receptor agonists in achieving higher-quality weight loss efficacy. The approved clinical indication for this approval is weight management for obese or overweight individuals with at least one weight-related comorbidity. https://finance.eastmoney.com/a/202511263575661579.html
- Source: drugdu
- 52
- November 27, 2025
CDMEE Chengdu

Organiser：Sichuan Provincial Hospital Association, Sichuan Medical Device Industry Association, Sichuan Rehabilitation Medicine Association Time： March 17 – 19, 2026 Address：No. 198, Shijicheng Road, Chengdu, Sichuan Province Exhibition hall：Chengdu Century City New International Convention & Exhibition Center Product range: Medical Equipment Exhibition Area: Imaging equipment, in vitro diagnostic reagents and instruments, disinfection and infection control series, medical electronic equipment, medical vehicles, operating room and emergency equipment, medical consumables and surgical consumables, medical maintenance parts and consumables, etc. Medical Laboratory Exhibition Area: Medical analysis systems, gene and life science instruments, laboratory case equipment and consumables, clinical laboratory equipment and consumables, blood collection management systems and blood transfusion supplies, blood and cell analysis systems, clinical laboratory equipment parts and maintenance consumables, etc. Rehabilitation and Well-being Exhibition Area: Sensory integration training equipment, disability aids and supplies, rehabilitation and physiotherapy equipment, sensory interaction equipment, assistive devices, etc.; sensory integration training equipment, disability equipment and supplies, ...
- Source: drugdu
- 68
- November 27, 2025
Fosun Pharma and Ruizhi Pharma Reach Strategic Cooperation

On November 25th, Fosun Pharma and Ruizhi Pharma…A strategic cooperation framework agreement signing ceremony was held in Shanghai. Li Xiang, Senior Vice President and CEO of the Global R&D Center of Fosun Pharma , stated that in the future, leveraging the full-chain R&D service capabilities of Ruizhi Pharma , Fosun Pharma is expected to further improve the efficiency and quality of its drug development across various drug types, accelerate the transformation of innovative achievements, and consolidate its competitive advantage in the field of innovative medicine. At the same time, the cooperation between the two parties sets a benchmark for the industry with a “technology-driven innovation platform + service platform” model, which will help promote the efficient integration of upstream and downstream resources in the industry chain, contribute to improving the overall level of new drug development in China, and bring more high-quality treatment options to more patients. https://finance.eastmoney.com/a/202511253574517765.html
- Source: drugdu
- 64
- November 26, 2025
Aurisco’s wholly-owned subsidiary received the marketing authorization for its Estradiol Tablets

November 25 – Aurisco (605116) announced that its wholly-owned subsidiary, Yangzhou Aurisco Pharmaceutical Co., Ltd., recently received the Drug Registration Certificate approved and issued by the National Medical Products Administration (NMPA) for Estradiol Tablets / Estradiol and Dydrogesterone Tablets Composite Packaging. The dosage form is tablets, with specifications as follows: each Estradiol Tablet contains 2mg of estradiol, and each Estradiol and Dydrogesterone Tablet contains 2mg of estradiol and 10mg of dydrogesterone. As of October 31, 2025, the cumulative R&D investment in this drug project by the company amounted to approximately RMB 12.64 million. This product is a dydrogesterone compound preparation originally developed by Abbott. It is used to treat perimenopausal syndrome caused by natural or surgical menopause. In 2015, the Estradiol Tablets / Estradiol and Dydrogesterone Tablets Composite Packaging, applied for by Abbott as an imported drug, was approved for marketing in China under the brand name “Femoston®”. Data from ...
- Source: drugdu
- 57
- November 26, 2025
Hengrui Pharma’s Ruikang Trastuzumab for Injection Wins Clinical Trial Approval

Beijing Business Today, Nov. 25 – Hengrui Pharmaceuticals announced that its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration (NMPA) for Ruikang Trastuzumab for Injection, approving the monotherapy clinical trial in patients with HER2-amplified solid tumors. According to the announcement, Ruikang Trastuzumab for Injection binds to and is internalized by HER2-expressing tumor cells. Within the tumor cell lysosomes, the toxin is released through protease cleavage, inducing cell cycle arrest and triggering tumor cell apoptosis. The released toxin exhibits high membrane permeability, enabling a bystander killing effect that further enhances anti-tumor efficacy. Ruikang Trastuzumab for Injection was approved for marketing in China in May 2025, indicated for the treatment of adult patients with unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring HER2 (ERBB2) activating mutations who have previously received at least one line of systemic ...
- Source: drugdu
- 59
- November 26, 2025
Honz Pharmaceutical Co., Ltd. has received the approval notice for the clinical trial of the cough-relieving orange-red granules drug

Beijing Business News (Reporter Ding Ning) – On the evening of November 25th, Honz Pharmaceutical Co., Ltd. (300086) issued a statement, announcing that recently, the company’s “Cough Suppressant Juhong Granules” has obtained the “Drug Clinical Trial Approval Notice” issued by the National Medical Products Administration. The announcement shows that Cough Suppressant Juhong Granules is a product that the company has already produced and is currently on sale. It was originally a national second-level protected traditional Chinese medicine variety (with a protection period until September 13, 2016), and its current indications are “clearing the lungs, suppressing cough, and resolving phlegm. It is used for cough with excessive phlegm, chest fullness, shortness of breath, dry throat and itchy throat caused by phlegm heat blocking the lungs.” Based on the latest clinical research and expert consensus, the company submitted a clinical trial application to add a new indication of “acute exacerbation of chronic ...
- Source: drugdu
- 53
- November 26, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.